Hypoxic hepatitis as a manifestation of a new coronavirus infection


DOI: https://dx.doi.org/10.18565/therapy.2022.2suppl.3-9

Abyzov A.S., Tarasova L.V., Busalaeva E.I.

1) Chuvash State University named after I.N. Ulyanov, Cheboksary, Russian Federation; 2) Institute of Postgraduate Medical Education of the Ministry of Healthcare of Chuvash Republic, Cheboksary, Russian Federation
Abstract. The liver is one of the target organs for a new coronavirus infection. The pathogenesis of coronavirus infection is multifactorial, one of the possible causes is hypoxia, which develops due to respiratory failure, which is a distinctive feature of COVID-19. Literature data on the pathogenesis of liver damage in a new coronavirus infection, including liver damage as a result of hypoxia, are presented.
Keywords: hypoxic hepatitis, new coronavirus infection, liver damage, hypoxia
Read entire article

Literature

1. Metawea M.I., Yousif W.I., Moheb I. COVID 19 and liver: An A–Z literature review. Dig Liver Dis. 2021; 53(2): 146–52. doi: 10.1016/j.dld.2020.09.010.


2. Amin M. COVID-19 and the liver: Overview. Eur J Gastroenterol Hepatol. 2021; 33(3): 309–11. doi: 10.1097/MEG.0000000000001808.


3. Chai X., Hu L., Zhang Y. et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. doi: 10.1101/2020.02.03.931766


4. Idalsoaga F., Ayares G., Arab J.P., Díaz L.A. COVID-19 and indirect liver injury: A narrative synthesis of the evidence. J Clin Transl Hepatol. 2021; 9(5): 760–68. doi: 10.14218/JCTH.2020.00140.


5. Lightsey J.M., Rockey D.C. Current concepts in ischemic hepatitis. Curr Opin Gastroenterol. 2017; 33(3): 158–63. doi: 10.1097/MOG.0000000000000355.


6. Premkumar M., Kedarisetty C.K. Cytokine storm of COVID-19 and its impact on patients with and without chronic liver disease. J Clin Transl Hepatol. 2021; 9(2): 256–64. doi: 10.14218/JCTH.2021.00055.


7. Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475–81. doi: 10.1016/S2213-2600(20)30079-5.


8. Tian D., Ye Q. Hepatic complications of COVID-19 anditstreatment. J Med Virol. 2020; 92(10): 1818–24. doi: 10.1002/jmv.26036.


9. Feng G., Zheng K.I., Yan Q.Q. et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020; 8(1): 18–24. doi: 10.14218/JCTH.2020.00018.


10. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 15 (22.02.2022). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/BMP_COVID-19_V15.pdf (дата обращения – 01.03.2022).


11. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420–22. doi: 10.1016/S2213-2600(20)30076-X.


12. Zippi M., Fiorino S., Occhigrossi G., Hong W. Hypertransaminasemia in the course of infection with SARS-CoV-2: Incidence and pathogenetic hypothesis. World J Clin Cases. 2020; 8(8): 1385–90. doi: 10.12998/wjcc.v8.i8.1385.


13. Rey J.R., Caro-Codon J., Rosillo S.O. et al.; CARD-COVID Investigators. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22(12): 2205–15. doi: 10.1002/ejhf.1990.


14. Aghemo A., Piovani D., Parigi T.L. et al.; Humanitas COVID-19 Task Force. COVID-19 digestive system involvement and clinical outcomes in a Large Academic Hospital in Milan, Italy. Clin Gastroenterol Hepatol. 2020; 18(10): 2366–68.e3. doi: 10.1016/j.cgh.2020.05.011.


15. Wang Y., Liu S., Liu H. et al. SARS-CoV-2 infection of the liver directly contributes o hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4): 807–16. doi: 10.1016/j.jhep.2020.05.002.


16. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420–22. doi: 10.1016/S2213-2600(20)30076-X.


17. Sharma A., Jaiswal P., Kerakhan Y. et al. Liver disease and outcomes among COVID-19 hospitalized patients – A systematic review and meta-analysis. Ann Hepatol. 2021; 21: 100273. doi: 10.1016/j.aohep.2020.10.001.


18. Del Zompo F., De Siena M., Ianiro G. et al. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: Systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020; 24(24): 13072–88. doi: 10.26355/eurrev_202012_24215.


19. Huang H., Li H., Chen S. et al. Prevalence and characteristics of hypoxic hepatitis in COVID-19 Patients in the Intensive Care Unit: a first retrospective study. Front Med (Lausanne). 2021; 7: 607206. doi: 10.3389/fmed.2020.607206.


Similar Articles

Back to Content

Бионика Медиа